Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide LAR in Metastatic Neuroendocrine Carcinomas
NCT01253161Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Feb 2011
- Primary completion
- Oct 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pasireotide LAR in neuroendocrine tumors (NETs), carcinoid tumor, sponsored by Moffitt Cancer Center. Started Feb 2011; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
neuroendocrine tumors (NETs)carcinoid tumor
Beyond the preview
Go deeper on NCT01253161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01253161.